Breast Cancer Test | GeneType | Genetic Technologies

Test your risk
of breast cancer

1 in 8 women in the US develop breast cancer during her lifetime1 – and most will have no significant family history. 2,3

That’s why geneType for Breast Cancer looks beyond family history.

Know your risk to learn more about your options to reduce that risk.

Breast Cancer Testing

Most breast cancers are diagnosed
in women with no significant family history2,3

There are a variety of risk factors that may influence your overall risk of breast cancer including:¹

Personalized risk score. Personalized health plan.

GeneType for Breast Cancer can help you and your health provider develop a risk reduction health plan just for you.

Depending on your risk, your health provider may consider:

  • Managing the risk factors you can change
  • Additional breast screening that may include mammograms, ultrasound and/or MRI
  • Risk-reducing medications (if appropriate)
  • Consultation with a specialist

Is geneType for Breast Cancer
right for you?

If you are 35 years of age and answered yes to having any of these risk factors we recommend geneType for Breast Cancer

On their own, each risk factor adds only a small amount of risk to your chances of developing breast cancer. But, together they may increase your risk to a point where a proactive approach is recommended. 

How many of these questions can you answer yes to?
I am 35 or older
I have been told I have dense breast tissue
I have not had a mammogram within the past year
I have a relative who has had breast cancer
I have taken (am taking) oral contraception
I gave birth to my first child after 30
I did not breastfeed
I have been taking hormone replacement therapy
I have started menopause
I’ve gained post-menopausal weight
I want to understand my “baseline” genetic risk

Uniquely powered to assess your risk

GeneType for Breast Cancer is the only test that gives you a comprehensive and highly accurate risk prediction score based on your:

  • Your own genetic markers of breast cancer risk
  • Your age
  • Your family history of breast cancer (if any)
  • Your body mass index
  • Your breast density from your last mammogram (if available)
  • Your menopausal status

If you order geneType through your medical practitioner, you will receive your results directly from them.

Unlock the power of your DNA

By looking at common markers of risk in your genes, we get a better picture of disease risk. We call this risk factor, gene risk.

Everyone has these markers, but not everyone has the same combination. Like a fingerprint, your genetic markers are unique to you, and can help define your “baselinerisk of developing breast cancer

Have questions? We have answers.

If your questions are not shown here, please contact us directly.

Can I order online?


You can order through our 3rd party telehealth provider in a few simple steps.

1. Register on our patient portal ( )

2. Select and pay for the test.

3. Fill out the clinical questions.

4. Once the telehealth provider approves your information, you will be sent a geneType test.

5. Follow the instructions to collect your DNA with a saliva tube.

6. Return your saliva sample in the mail and wait for results.

7. Review next steps with your telehealth provider.

What will my geneType for Breast Cancer results tell me?

Your results will tell you, based on genetics and other risk factors, your risk for developing sporadic breast cancer over two different time periods: in the next 5 years and in your remaining lifetime.

You and your healthcare provider can use this information to develop a personalized screening and risk reduction plan

If I already get my regular mammogram, do I still need to know my breast cancer risk score?

Great work maintaining your routine mammogram screening!

Your Breast Cancer risk score can also help you and your healthcare provider develop a personalized screening plan for you, which may involve additional screening than just mammogram alone.

If my risk of breast cancer is not elevated, can I skip my mammogram screenings?


Your geneType for Breast Cancer results will indicate whether you are at increased risk, or average risk. If you are at average risk, it is still important to follow the recommended screening guidelines for women of your age.

What ethnicities are eligible for geneType for Breast Cancer?

GeneType for Breast Cancer is clinically validated for women of African American, Caucasian & Hispanic descent. The risk model incorporates ethnicity-specific polygenic risk scores and population incidence data for patients of African American and Hispanic American descent derived from the Surveillance, Epidemiology, and End Results Program (SEER), however, the model has not been validated in these populations as yet.

What do I do with my results?

If you ordered geneType through your own health provider, you will receive your results directly from them. 

Will insurance cover this test?

This test is not generally covered by insurance. However, you may use FSA/HSA to pay for the test. Your ordering healthcare provider will discuss the cost of the test with you. A credit card authorization form will be included in the test kit that lists the payment options. Or you will be able to pay via the geneType patient portal.

Know your risk of breast cancer so you can take action

Interested in ordering more than one disease? Order geneType Multi-Test.

See individual disease pages for more information about each test.

The Multi-Risk suite of tests is for adults 40-69 years of age. At maximum, a woman would be eligible for 5 diseases in the panel; a man would be eligible for 4. If patient is younger than 40, they may qualify for geneType's breast or colorectal risk assessments only.

Coming soon: melanoma, pancreatic cancer and atrial fibrillation geneType tests. Patient eligibility dependent on personal medical history, age, sex and self-identified race/ethnicity

What’s happening?

  1. American Cancer Society (2012). Accessed June 2022.
  2. van der Groep P et al. Cell Oncol (Dordr) 2011;34:71–88.
  3. Shiyanbola OO et al. Cancer Epidemiol Biomarkers Prev 2017;26:1753–60.
  4. Dite GS et al. Cancer Epidemiol Biomarkers Prev 2016;25:359–65.

Keep up-to-date with our latest advances 

Sign up to our newsletter to stay informed about our latest advances and how these could support your practice.

Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356